Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53

Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy

(2019) Mario Negrette-Guzmán   EUROPEAN JOURNAL OF PHARMACOLOGY

Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies

(2019) NaNa Keum et al.   Nature Reviews Gastroenterology & Hepatology

Development of artemisinin resistance in malaria therapy

(2019) Janine Naß et al.   PHARMACOLOGICAL RESEARCH

Interactions of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer

(2019) Beyer et al.   Cancers

Targeting the death receptor signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

(2018) Reyhaneh Moradi Marjaneh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Trends in colorectal cancer incidence among younger adults-Disparities by age, sex, race, ethnicity, and subsite

(2018) Amanda B. Crosbie et al.   Cancer Medicine

Death receptor 5 is activated by fucosylation in colon cancer cells

(2018) Baojie Zhang et al.   FEBS Journal

Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action

(2017) Yin Kwan Wong et al.   MEDICINAL RESEARCH REVIEWS

In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil

(2017) Angélique Virgone-Carlotta et al.   PLoS One

Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).

(2017) A. D. Baron et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).

(2017) C. S. Rocha Lima et al.   JOURNAL OF CLINICAL ONCOLOGY

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

(2016) Zhe Li et al.   MOLECULES

Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold

(2016) Mithun Rudrapal et al.   Drug Design Development and Therapy

Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial

(2016) Peter G. Kremsner et al.   PLOS MEDICINE

A Brief History of Qinghaosu

(2015) Nicholas J. White et al.   TRENDS IN PARASITOLOGY

Artesunate Induces Cell Death in Human Cancer Cells via Enhancing Lysosomal Function and Lysosomal Degradation of Ferritin

(2014) Nai-Di Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells

(2014) Yvonne Möller et al.   PLoS One

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†

(2013) A. L. Cohn et al.   ANNALS OF ONCOLOGY

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer

(2013) Charles S. Fuchs et al.   CANCER

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

(2013) Zev A. Wainberg et al.   Clinical Colorectal Cancer

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

(2012) S. Surget et al.   CANCER RESEARCH

Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer

(2012) Carmine Stolfi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study

(2012) Robert Miller et al.   MALARIA JOURNAL

Correction: Dihydroartemisinin Enhances Apo2L/TRAIL-Mediated Apoptosis in Pancreatic Cancer Cells via ROS-Mediated Up-Regulation of Death Receptor 5

(2012) Rui Kong et al.   PLoS One

Artemisinin: Discovery from the Chinese Herbal Garden

(2011) Louis H. Miller et al.   CELL

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

(2011) Maria P. Crespo-Ortiz et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration

(2011) Carrie A Morris et al.   MALARIA JOURNAL

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants

(2011) C R Reis et al.   Cell Death & Disease

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells

(2010) Qin He et al.   CANCER BIOLOGY & THERAPY